VisionGate Announces an Exclusive Global License, Manufacturing and Supply Agreement for Iloprost, VisionGate’s Phase 2 Oral Lung Cancer Interception Drug
22 août 2019 08h00 HE
|
VisionGate, Inc.
Seattle, WA, Aug. 22, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has finalized an exclusive worldwide license...
VisionGate Announces Lung Cancer Prevention Trial Progress
29 janv. 2019 11h32 HE
|
VisionGate, Inc.
Seattle, WA, Jan. 29, 2019 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, announces that it has selected PCI Pharma Services to provide...
VisionGate, Inc. Appoints R. John Glasspool as Chief Operating and Strategy Officer and member of the Board of Directors
11 oct. 2018 10h06 HE
|
VisionGate, Inc.
Seattle, WA, Oct. 11, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., an integrated, clinical-stage, oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of R. John...
VisionGate’s Cell-CT™ Platform Uses 3D Cell Morphometry and Artificial Intelligence to Detect an Immunotherapy Predictive Biomarker and Cancer-Associated Cells that have undergone Malignancy Associated Change (MAC) from Liquid Biopsy
24 sept. 2018 06h00 HE
|
VisionGate, Inc.
Seattle, WA, Sept. 24, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company announces two peer-reviewed poster presentations at the International...
VisionGate Announces New Appointment to the Board of Directors
14 juin 2018 14h06 HE
|
VisionGate, Inc.
SEATTLE, WA, June 14, 2018 (GLOBE NEWSWIRE) -- VisionGate is pleased to announce the appointment of Dr. James S. (Jim) Burns to the Board of Directors, expanding the depth of biotech leadership and...
VisionGate, Inc. Appoints Randal Buness as Chief Financial Officer
17 avr. 2018 18h34 HE
|
VisionGate, Inc.
SEATTLE, WA, April 17, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce the appointment of Randal Buness, CPA, MBA as...
VisionGate’s Cell-CT™ 3D Cellular Imaging Platform Detects the Presence of Cancer-Associated Cells (CACs) that have undergone Malignancy Associated Change (MAC)
16 avr. 2018 09h23 HE
|
VisionGate, Inc.
SEATTLE, WA, April 16, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, today presented a breakthrough research study demonstrated its Cell-CT™...
VisionGate Lung Cancer 3D Cellular Imaging Research to be Featured as a Late-Breaking Abstract at the AACR Annual Meeting 2018
12 avr. 2018 13h46 HE
|
VisionGate, Inc.
SEATTLE, WA, April 12, 2018 (GLOBE NEWSWIRE) -- VisionGate, Inc., a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce that new lung cancer 3D cellular imaging...
VisionGate is Leveraging the Cell-CT™ Platform to Expand Cancer Diagnostics Services, Biopharmaceutical Services and Cancer Prevention Medicines
05 avr. 2018 14h03 HE
|
VisionGate, Inc.
SEATTLE, WA, April 05, 2018 (GLOBE NEWSWIRE) -- VisionGate, a clinical stage oncology pharmaceutical and diagnostics company, is pleased to announce today the advancement of its breakthrough...
VisionGate Announces Two New Appointments to the Board of Directors
04 avr. 2018 16h21 HE
|
VisionGate, Inc.
SEATTLE, WA, April 04, 2018 (GLOBE NEWSWIRE) -- VisionGate is pleased to announce the appointment of two new members to the Board of Directors, significantly expanding the depth of biotech...